Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Garsorasib on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Garsorasib is a targeted tablet for advanced non-small cell lung cancer (NSCLC) driven by a gene change called KRAS G12C. It was discovered by InventisBio in Shanghai, where it was known as D-1553, and is sold in China by the Chia Tai Tianqing group as 安方宁® (Anfangning®).
China's National Medical Products Administration (NMPA) granted it conditional approval in November 2024, through priority review, for adults with:
The mutation must be confirmed by a validated test before it is prescribed. It is a prescription lung cancer medicine and should only be used under an oncologist.
KRAS works like a switch that turns cell growth on and off. The G12C mutation jams that switch in the "on" position, so the cancer cells keep getting the message to grow. Garsorasib attaches to the faulty KRAS G12C protein and holds it in its inactive form, which cuts off the growth signal inside the tumour cell.
It is designed only for tumours with this exact mutation, so it is not used for lung cancers driven by other gene changes.
The approval rests on the D1553-102 phase 2 study, run at 43 hospitals in China and published in The Lancet Respiratory Medicine in 2024. It enrolled 123 adults whose KRAS G12C lung cancer had grown after platinum chemotherapy and immunotherapy. In the updated analysis used in the Chinese label:
This is a conditional approval based on a single-arm study. Full approval depends on the results of a confirmatory trial.
If a dose is more than 4 hours late, skip it and carry on with the next planned dose. If you vomit after taking it, do not take another dose. For side effects, the oncologist may pause treatment or step the dose down to 600 mg once a day, and then to 400 mg once a day.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Liver effects: this is the main safety concern. In 306 patients on the recommended dose, liver-related side effects occurred in 62.7%, and were severe (grade 3 or 4) in 28.1%, mostly as raised liver enzymes. Liver tests are done before starting, every 3 weeks for the first 3 months, and then monthly. In the trials, severe liver changes settled after the dose was paused or lowered, and no liver-related deaths were reported. People with existing liver disease need careful assessment first.
Overall: 35.0% of patients needed a pause or a lower dose because of side effects, but only 1.6% had to stop treatment for good. Safety in children and during breastfeeding has not been established, so discuss this with your doctor.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The tablets can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit.
No. It is approved only in China. It has no CDSCO approval, it is not sold in Indian pharmacies, and the US FDA and European Medicines Agency have not approved it either.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. For lung cancers with other driver mutations, see our pages on Hernexeos (HER2) and Ibtrozi (ROS1).
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. Each bottle holds 42 tablets of 200 mg, which is one week of treatment at six tablets a day, so four bottles cover about a month. The label says to keep the bottle sealed below 30°C, and it travels that way under temperature-controlled shipping. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the patient or the treating hospital on a valid oncologist's prescription.
Lung cancer specialists in Delhi see patients from all over North India, and being close to our New Delhi dispatch point keeps weekly refills simple.
Oncologists in Mumbai can request the tablets for a named patient once the KRAS G12C test report is ready.
Patients in Bangalore can receive a month's supply at a time, delivered to home or to the treating hospital.
A leading centre for thoracic oncology in South India, with experience in imported targeted therapies.
We time deliveries around the regular liver test visits so patients in Hyderabad stay on schedule.
For Kolkata and the eastern states, we share the quote and timeline before anything is ordered.
Patients in Pune can use the same documented import route, with updates at each stage.
Oncologists in Ahmedabad can send us the prescription and molecular report to begin the import.
Serves patients from Punjab, Haryana and Himachal Pradesh, with delivery to the patient or the cancer centre.
Patients in Rajasthan can continue oral treatment at home without travelling for each refill.
We coordinate delivery to public and private cancer hospitals across Uttar Pradesh.
Patients across Kerala can have the tablets delivered in Kochi and nearby cities.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
